NCT07328581: An ongoing trial by iCell Gene Therapeutics
This trial is ongoing. It must report results 3 years, 2 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT07328581 |
|---|---|
| Title | A Phase IIa, Open-Label, Single-Arm Study With an Initial Safety Run-In and Dose Expansion of ICG318 (BCMA-CD19-IL-15/IL15sushi cCAR T) in Participants With Refractory Systemic Lupus Erythematosus, With or Without Lupus Nephritis |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 30, 2026 |
| Completion date | Dec. 31, 2028 |
| Required reporting date | Dec. 31, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Oct. 21, 2026 |
| Days late | None |